AstraZeneca released primary analysis showing that the company’s AZD1222 vaccine demonstrated 76 percent efficacy against symptomatic Covid-19, 100 percent efficacy against severe or critical disease and hospitalizations, and 85 percent efficacy against symptomatic Covid-19 in people 65 years and older.

Vaccitech, which partnered with AstraZeneca and Oxford University on the development and manufacturing of that company’s Covid-19 vaccine, raised $168 million in a Series B financing round that will be used to support development of its own lead candidates in oncology and infectious disease.

A World Health Organization (WHO) vaccine safety panel said on March 17 that it considers that the benefits of the AstraZeneca Covid-19 vaccine outweigh its risks and recommends that vaccinations continue.

Preliminary data from a study conducted at the University of Oxford indicates that the Covid-19 vaccine developed by AstraZeneca is effective against the Brazilian variant P1, a source with knowledge of the study told Reuters on March 5.

The gout medication colchicine will be tested in a large UK study looking into potential early-stage Covid-19 treatments and enrollment criteria was widened for the latest arm of the trial, University of Oxford researchers said on March 3.

AstraZeneca and Oxford University’s Covid-19 vaccine is more effective when its second dose is given three months after the first, instead of six weeks, a peer-reviewed study published in The Lancet medical journal showed on Feb. 19.

As the world awaits the production and distribution of hundreds of millions of doses of COVID-19 vaccines that have been granted emergency use authorization, biopharmaceutical companies and manufacturers are developing the next wave of vaccines and therapeutics to combat the pandemic.

The World Health Organization listed AstraZeneca’s Covid-19 vaccine for emergency use, widening access in the developing world, while sources said the EU is in talks with Moderna on buying more vaccines.

The World Health Organization (WHO) on Feb. 15 listed AstraZeneca and Oxford University’s Covid-19 vaccine for emergency use, widening access to the relatively inexpensive shot in the developing world.

The University of Oxford launched a study to assess the safety and immune response of the Covid-19 vaccine the company has developed with AstraZeneca Plc in children for the first time.